S_inmary To define regions of deletion of chromosome 6q in breast cancer, we scored 18 (CA), microsatellites for allelic imbalance (AI) in 42 paired blood/tumour samples. Heterozygosity frequencies of the markers in the sample population ranged from 31% to 92% (mean 68%). Two regions of the chromosome arm showed Al values greater than the background range of 10-22% (mean 17%) of informative cases that was observed with five markers spanning 6q21 -q25.2. Firstly, seven markers gave Al values that averaged 35% in a region flanked by D6S313 (Al = 10%) at 6ql3 and D6S283 (Al = 17%) at 6qI6.3-21. The second region showed marginally increased Al at 6q25.2-q27 and included D6S193, previously shown to be close to a tumoursuppressor gene involved in ovarian carcinoma. Since Al of 6q in breast cancer was shown previously to be due predominantly to loss of heterozygosity, our results suggest the presence of at least two tumour-suppressor genes on 6q that are involved in breast cancer. The proximal region has not been recognised in breast cancer before and is involved in a higher frequency of tumours than the distal region.
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The involvement of several tumour-suppressor genes in cancers of the colon (Vogelstein et al., 1988) , breast (Mackay et al., 1988; Devilee et al., 1989 Devilee et al., , 1991 Cropp et al., 1990; Sato et al., 1990) , kidney (Zbar et al., 1987; Morita et al., 1991) , liver (Fujimonr et al., 1991) , lung (Kok et al., 1987 , Yokota et al., 1987 and bladder (Fearon et al., 1985) has been inferred from loss of constitutional heterozygosity (LOH) studies using molecular analysis of polymorphic genetic markers. In all these types of cancer, losses of multiple regions have been identified.
Deletions of parts of the long arm of chromosome 6 have been reported in breast carcinoma (Devilee et al., 1991) , ovarian carcinoma (Lee et al., 1990; Sato et al., 1990; Zheng et al., 1991; Saito et al., 1992a; Cliby et al., 1993; Foulkes et al., 1993 ) B-cell Non-Hodgkin's lymphoma (B-NHL) (Gaidano et al., 1992) , T-cell acute lymphocytic leukaemia (T-ALL) (Menasce et al., 1994) and malignant melanoma (Trent et al., 1989) . These results suggest the presence of one or more tumour-suppressor genes on chromosome 6q, an idea supported by chromosome-mediated transfer experiments (Trent et al., 1990 ). Devilee et al. (1991 reported a combined allelic imbalance (Al) at D6S37 (6q26-q27) and MYB (6q23.3-q24) of 50% in 42 informative patients. Furthermore, 90% of the allelic imbalance was shown to be due to allele loss rather than gain. Because these authors described 6q as 'the second most frequent site after 17p for LOH in breast cancer', we have carried out a detailed analysis of Al in malignant breast tumours from 42 patients using 18 recently described highly polymorphic dinucleotide repeat sequences (Weber and May, 1989; Weber, 1990) distributed along the length of 6q.
Materal and meod

Patients and tissues
Blood and tumour samples were collected from 42 unrelated breast cancer patients with full clinical details. Their diagnoses were infiltrating ductal in 34 patients, infiltrating lobular in six, mucoid in one and indeterminate in one case.
Preparation of high molecular ,eight DNA The isolation of genomic DNA from blood lymphocytes and breast tumour tissues was performed as previously described (Sambrook et al., 1989 (Orphanos et al., 1993 (Orphanos et al., , 1994 Allele analtsis Blood and tumour DNA samples from 42 patients with breast cancer were amplified by PCR to give radiolabelled products and analysed as described previously (Orphanos et al., 1993) . Quantification of the autoradiographic signals was performed with a 425S phosphorimager and Image Quant software supplied by Molecular Dynamics. The ratio of allele intensities in the tumour sample (T) relative to that in lymphocyte DNA (B) was calculated from T = Tl/T2 and B = Bl/B2, where TI and T2 and Bi and B2 correspond to the intensities of alleles I and 2 in the tumour and the blood samples respectively. Factors of T/B <0.5 or T/B >2.0 were arbitrarily considered to respresent Al evidence for LOH. Samples that showed Al ratios close to 0.5 or 2.0 were either rerun on a denaturating gel or their analysis was repeated using fresh blood/tumour sample aliquots. Figure 2 ). Between these two sets of loci was observed the most frequent Al (mean = 35.3%) in a region that contained seven loci between D6S280 at 6ql3 and D6S286 at 6ql6.3-q21. Marginally increased Al was observed with D6S220 (26%) at 6q25.2-q27 and D6S193 (27.5%) at 6q27.
We amplified all 18 markers from the blood/tumour DNA pairs of 20 patients and 17 markers from another six patients. From the data shown in Table III Since 92% of the tumours in the subset were of ductal onrgin compared with 81% in the total, it was not surprising to observe that the percentage Al values for loci in the subset reflected those seen within the data for all 42 patients samples. On the other hand, both lobular tumours (nos. 7 and 32) for which complete data were obtained showed Al at D6S261 and D6S359, distal to the major region of imbalance in ductal tumours. The small sample sizes did not allow us to determine the statistical significance of these observations and no other trends were observed.
The markers used in this study were regionally localised by hybrid cell deletion mapping (Orphanos et al., 1994) , fluorescence in situ hybridisation (FISH) (Menasce et al., 1994) and by genetic linkage (Weissenbach et al., 1992) . The order of markers given in this paper is that of the current consensus map of 6q (Volz et al., 1994) al., 1989) and deletions in acute lymphocytic leukaemia at 6ql6.3-q21 (Menasce et al., 1994) .
Distal 6q was implicated as a region of high LOH by Devilee et al. (1991) , the combined LOH of D6S37 (6q27) and MYB (6q23-q24) being 50% in 42 informative patients. The practice of grouping loci together to obtain a combined frequency for Al or LOH (Takita et al., 1992; Dodson et al., 1993) is not necessarily informative because the more markers that are involved the greater will be the additive effect of random losses. Thus, in our study, 16 of 26 (62%) tumours showed Al at one or more of the nine markers in the region 6ql3-q21 (D6S313-D6S283), and 15 of 26 (58%) tumours showed Al at one or more of the nine markers in the distal region 6q21-q27 (D6S261-D6S281).
Region 6q27, reported to show high LOH in serous ovarian tumours (Saito et al., 1992a) , appears to show only marginally raised LOH (27.5%) at D6S193 in our study, suggesting that the implied associated tumour suppressor may be of lesser importance in breast cancer than in ovarian carcinoma.
